SiteOne Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $100M
Overview
Developing non-opioid small molecule drugs for neurological pain and disorders.
NeurosciencePainPsychiatry
Technology Platform
A platform for discovering selective small molecule inhibitors of specific sodium ion channels (e.g., Nav1.7) for neurological and psychiatric conditions.
Funding History
1Total raised:$100M
PIPE$100M
Opportunities
Addressing the massive unmet need for safe, effective, non-addictive pain therapeutics amid the opioid crisis.
Risk Factors
Clinical validation risk for a novel mechanism in pain, and potential for unforeseen off-target effects despite selective design.
Competitive Landscape
Operates in the competitive non-opioid pain market, competing with other channel-focused biotechs and large pharma, with differentiation claimed through selectivity.